雌激素β受体在恶性黑素瘤中的研究进展  

Role of estrogen receptorβ in malignant melanoma

作　　者：张亚美 陶玥[1] 包军[1] 

机构地区：[1]南京大学医学院附属鼓楼医院皮肤性病科,210008

出　　处：《国际皮肤性病学杂志》2017年第5期313-316,共4页International Journal of Dermatology and Venereology

基　　金：江苏省自然科学基金（BK20150111）

摘　　要：越来越多的研究提示，恶性黑素瘤是一种激素依赖性肿瘤，其发病率男性高于女性，女性患者预后较好。β受体是黑素瘤中主要的雌激素受体，可以抑制细胞增殖，具有抑癌作用。随着肿瘤的进展，其表达量逐渐下降，与恶性黑素瘤的发生发展密切相关。女性雌激素β受体水平明显高于男性，可能与恶性黑素瘤女性患者预后更好相一致。未来雌激素受体β及其激动剂可作为评价预后的重要标志及新的治疗策略。Increasing evidences support that malignant melanoma （MM） is a kind of hormone- dependent tumor, its incidence is usually higher in males than in females, and the prognosis is better in female patients. Estrogen receptor β （ERβ）is the predominant ER in melanoma, and can inhibit the proliferation of melanocytes to exert antitumor effect. With the development of tumors, the expression of ERβ is gradually decreased, suggesting that ERβis closely associated with the occurrence and development of MM. Females show an obvious higher level of ERβ compared with males, which is consistent with better prognosis in female patients with MM. In the future, ERβ is likely to be a marker for prognostic assessment, and its agonists may serve as a new treatment strategy.

关 键 词：黑色素瘤 黑素细胞 雌激素类 雌激素受体Β 信号传导 细胞增殖 

分 类 号：R739.5[医药卫生—肿瘤]